After the 5-time initiation period, we modified the dose during the first 4 weeks using standardized dose-adjustment methods,5,10 starting with the doses predicted by the algorithms and producing the same relative adjustments based on the INR in both study groupings. Clinicians were educated of the relative dosage transformation at each INR measurement but not the actual dosage of warfarin. Clinicians could contact the medical monitor to request an override of the relative dose adjustments without having to be informed of the real dose.We believe tivozanib’s promising tolerability and efficacy profile suggests the potential for broad applicability and combinability with chemotherapies and additional targeted brokers. We are currently evaluating tivozanib as a single-agent and in conjunction with approved brokers in medical trials in RCC, gastrointestinal, metastatic breast, and lung cancers. We look forward to the chance of continuing to collaborate with the global medical oncology community to advance these efforts. The Stage 2 scientific trial evaluated tivozanib in 272 patients with advanced RCC. Data demonstrated that the median progression-free survival achieved by individuals with advanced apparent cell RCC who had undergone a prior nephrectomy was 14.8 months – comparing favorably to historical data from trials testing other currently accepted multikinase inhibitors in RCC.